Acoltremon 0.003% · ophthalmic solution
Dry Eye/OSD
Approved uses
Dry eye disease
One drop in each eye twice daily, about 12 hours apart
A TRPM8 agonist: it drives trigeminal signaling to increase basal tear production rather than supplementing tears
Contraindications
None.
0.003% ophthalmic solution, 0.4 mL single-dose vials in packs of 60
Studies in animals suggest that acoltremon, the active substance in TRYPTYR, is an agonist of transient receptor potential melastatin 8 (TRPM8) thermoreceptors. TRPM8 thermoreceptor stimulation has been shown to activate trigeminal nerve signaling leading to increased basal tear production. The exact mechanism of action for TRYPTYR in dry eye disease is unknown.
Warnings & Precautions
- Eye injury and contamination: to avoid them, do not touch the vial tip to the eye or any other surface.
- Contact lenses: do not instill TRYPTYR while wearing contact lenses; remove them first, and they may be reinserted 15 minutes after the dose.
Common Side Effects
The most common adverse reaction was instillation site pain (50%).
Pregnancy: No adequate and well-controlled studies in pregnant women; systemic exposure to acoltremon from ocular administration is negligible. Intravenous acoltremon in pregnant rats and rabbits during organogenesis did not produce embryofetal toxicity at 806- and 2151-fold the maximum recommended human ocular dose.
Lactation: No data on the presence of acoltremon in human milk, the effects on the breastfed infant, or the effects on milk production; systemic exposure following topical ocular administration is low.
The safety and effectiveness of TRYPTYR have not been established in pediatric patients.